Vestal Point Capital LP Makes New $8.64 Million Investment in Sanofi (NASDAQ:SNY)

Vestal Point Capital LP acquired a new stake in Sanofi (NASDAQ:SNY) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 150,000 shares of the company’s stock, valued at approximately $8,644,000.

Several other large investors also recently modified their holdings of SNY. B. Riley Wealth Advisors Inc. increased its stake in shares of Sanofi by 32.4% during the first quarter. B. Riley Wealth Advisors Inc. now owns 20,925 shares of the company’s stock worth $1,122,000 after purchasing an additional 5,117 shares during the period. Tidal Investments LLC acquired a new stake in shares of Sanofi during the first quarter worth $228,000. Atria Investments Inc lifted its holdings in shares of Sanofi by 31.1% during the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock worth $4,805,000 after buying an additional 23,463 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of Sanofi by 245.4% in the first quarter. Cetera Investment Advisers now owns 178,349 shares of the company’s stock valued at $8,668,000 after acquiring an additional 126,712 shares during the period. Finally, Cetera Advisors LLC grew its stake in shares of Sanofi by 301.6% in the first quarter. Cetera Advisors LLC now owns 60,359 shares of the company’s stock valued at $2,933,000 after acquiring an additional 45,330 shares in the last quarter. 10.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on SNY. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Trading Up 0.9 %

Shares of Sanofi stock opened at $48.72 on Friday. The firm’s 50-day moving average price is $53.17 and its two-hundred day moving average price is $52.15. The company has a market capitalization of $123.64 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 1.23 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter last year, the business posted $2.55 EPS. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, analysts forecast that Sanofi will post 4.29 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.